ARMATA PHARMACEUTICALS INC REPORTS Q4 2025 NET LOSS OF $3.42 PER SHARE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy ARMP?
Source: moomoo
Company Overview: Armata Pharmaceuticals reported a net loss of $3.42 per share for the fourth quarter of 2025.
Financial Performance: The significant loss indicates challenges in the company's financial health during this period.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARMP
Wall Street analysts forecast ARMP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.150
Low
9.00
Averages
12.00
High
15.00
Current: 9.150
Low
9.00
Averages
12.00
High
15.00
About ARMP
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Armata Receives FDA Fast Track Designation for AP-SA02
- FDA Fast Track Designation: Armata Pharmaceuticals' AP-SA02 has received Fast Track designation from the FDA, marking a significant advancement in the treatment of antibiotic-resistant bacterial infections and is expected to expedite the clinical development and approval process.
- Clinical Study Plans: The Phase 3 superiority study for AP-SA02 is anticipated to begin in the second half of 2026, aiming to evaluate its efficacy against complicated Staphylococcus aureus bacteremia, potentially providing new treatment options for patients.
- Funding Support Background: The clinical development of this project is partially supported by a $26.2 million Department of Defense grant, highlighting government emphasis on the development of new therapies and providing robust financial backing for Armata's research efforts.
- Market Demand Response: The Fast Track designation for AP-SA02 not only reflects the seriousness of complicated Staphylococcus aureus bacteremia but also underscores the urgent market need for effective new treatment options, which may enhance Armata's competitiveness in the biopharmaceutical sector.
See More
Armata Pharmaceuticals Q4 Earnings Report Analysis
- Poor Financial Performance: Armata Pharmaceuticals reported a Q4 GAAP EPS of -$3.42, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Revenue Decline: The company generated $1.1 million in revenue, an 8.3% year-over-year decrease, reflecting weak product sales and the potential need to reassess market strategies to restore growth.
- Cash Flow Situation: As of December 31, 2025, Armata held approximately $14.1 million in cash and cash equivalents, down from $14.8 million in the same period of 2024, indicating liquidity pressures that may affect future operations.
- Uncertain Market Outlook: While Armata has potential in the antibiotic adjunct space, there are numerous red flags regarding its future development, which may lead to investor concerns about its long-term value.
See More
ARMATA PHARMACEUTICALS INC REPORTS Q4 2025 NET LOSS OF $3.42 PER SHARE
Company Overview: Armata Pharmaceuticals reported a net loss of $3.42 per share for the fourth quarter of 2025.
Financial Performance: The significant loss indicates challenges in the company's financial health during this period.
See More
Armata Pharmaceuticals Delays 2025 Financial Reporting
- Financial Reporting Delay: Armata Pharmaceuticals announced a delay in reporting its fourth-quarter and full-year 2025 results, expecting to file by March 31, 2026, which may impact investor confidence and lead to stock price volatility.
- FDA Qualification: The company's lead candidate AP-SA02 has received Qualified Infectious Disease Product status from the FDA, making it eligible for development incentives, including extended market exclusivity, thereby enhancing its market potential in treating serious Staphylococcus aureus infections.
- Clinical Trial Plans: Armata plans to advance AP-SA02 into a Phase 3 trial in the second half of 2026, based on positive Phase 2a results showing higher cure rates and strong responses in patients with complicated Staphylococcus aureus infections, indicating the drug's effectiveness.
- Manufacturing Facility Commissioned: The company has commissioned its cGMP manufacturing facility in Los Angeles to support future clinical and commercial production, marking a significant advancement in Armata's production capabilities and potentially laying the groundwork for future drug launches.
See More
Armata Pharmaceuticals Delays Financial Results and Receives FDA Recognition
- Financial Reporting Delay: Armata Pharmaceuticals announced a delay in releasing its Q4 and full-year 2025 financial results, with a 10-K filing expected by March 31, 2026, indicating complexities in financial reporting and a commitment to compliance.
- FDA Recognition for New Therapy: The company's AP-SA02 product has received FDA's Qualified Infectious Disease Product (QIDP) designation for treating complicated Staphylococcus aureus bacteremia, highlighting its potential in antibiotic resistance treatment and possibly enhancing market competitiveness.
- Clinical Trial Advancement: The FDA confirmed that data from Armata's Phase 2a diSArm study is sufficient to initiate a Phase 3 clinical trial anticipated to start in the second half of 2026, which, if successful, could provide a new treatment avenue for antibiotic resistance, holding significant strategic implications.
- Manufacturing Facility Commissioned: Armata's state-of-the-art cGMP manufacturing facility in Los Angeles has been formally commissioned, featuring 56,000 square feet of space and advanced production capabilities to support future clinical trials and commercialization, aligning with the U.S. government's focus on securing the supply chain for essential medicines.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Armata Receives FDA Fast Track Designation for AP-SA02
- FDA Fast Track Designation: Armata Pharmaceuticals' AP-SA02 has received Fast Track designation from the FDA, marking a significant advancement in the treatment of antibiotic-resistant bacterial infections and is expected to expedite the clinical development and approval process.
- Clinical Study Plans: The Phase 3 superiority study for AP-SA02 is anticipated to begin in the second half of 2026, aiming to evaluate its efficacy against complicated Staphylococcus aureus bacteremia, potentially providing new treatment options for patients.
- Funding Support Background: The clinical development of this project is partially supported by a $26.2 million Department of Defense grant, highlighting government emphasis on the development of new therapies and providing robust financial backing for Armata's research efforts.
- Market Demand Response: The Fast Track designation for AP-SA02 not only reflects the seriousness of complicated Staphylococcus aureus bacteremia but also underscores the urgent market need for effective new treatment options, which may enhance Armata's competitiveness in the biopharmaceutical sector.
See More
Armata Pharmaceuticals Q4 Earnings Report Analysis
- Poor Financial Performance: Armata Pharmaceuticals reported a Q4 GAAP EPS of -$3.42, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Revenue Decline: The company generated $1.1 million in revenue, an 8.3% year-over-year decrease, reflecting weak product sales and the potential need to reassess market strategies to restore growth.
- Cash Flow Situation: As of December 31, 2025, Armata held approximately $14.1 million in cash and cash equivalents, down from $14.8 million in the same period of 2024, indicating liquidity pressures that may affect future operations.
- Uncertain Market Outlook: While Armata has potential in the antibiotic adjunct space, there are numerous red flags regarding its future development, which may lead to investor concerns about its long-term value.
See More
ARMATA PHARMACEUTICALS INC REPORTS Q4 2025 NET LOSS OF $3.42 PER SHARE
Company Overview: Armata Pharmaceuticals reported a net loss of $3.42 per share for the fourth quarter of 2025.
Financial Performance: The significant loss indicates challenges in the company's financial health during this period.
See More
Armata Pharmaceuticals Delays 2025 Financial Reporting
- Financial Reporting Delay: Armata Pharmaceuticals announced a delay in reporting its fourth-quarter and full-year 2025 results, expecting to file by March 31, 2026, which may impact investor confidence and lead to stock price volatility.
- FDA Qualification: The company's lead candidate AP-SA02 has received Qualified Infectious Disease Product status from the FDA, making it eligible for development incentives, including extended market exclusivity, thereby enhancing its market potential in treating serious Staphylococcus aureus infections.
- Clinical Trial Plans: Armata plans to advance AP-SA02 into a Phase 3 trial in the second half of 2026, based on positive Phase 2a results showing higher cure rates and strong responses in patients with complicated Staphylococcus aureus infections, indicating the drug's effectiveness.
- Manufacturing Facility Commissioned: The company has commissioned its cGMP manufacturing facility in Los Angeles to support future clinical and commercial production, marking a significant advancement in Armata's production capabilities and potentially laying the groundwork for future drug launches.
See More
Armata Pharmaceuticals Delays Financial Results and Receives FDA Recognition
- Financial Reporting Delay: Armata Pharmaceuticals announced a delay in releasing its Q4 and full-year 2025 financial results, with a 10-K filing expected by March 31, 2026, indicating complexities in financial reporting and a commitment to compliance.
- FDA Recognition for New Therapy: The company's AP-SA02 product has received FDA's Qualified Infectious Disease Product (QIDP) designation for treating complicated Staphylococcus aureus bacteremia, highlighting its potential in antibiotic resistance treatment and possibly enhancing market competitiveness.
- Clinical Trial Advancement: The FDA confirmed that data from Armata's Phase 2a diSArm study is sufficient to initiate a Phase 3 clinical trial anticipated to start in the second half of 2026, which, if successful, could provide a new treatment avenue for antibiotic resistance, holding significant strategic implications.
- Manufacturing Facility Commissioned: Armata's state-of-the-art cGMP manufacturing facility in Los Angeles has been formally commissioned, featuring 56,000 square feet of space and advanced production capabilities to support future clinical trials and commercialization, aligning with the U.S. government's focus on securing the supply chain for essential medicines.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
